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Abstract
There is evidence of increased microglial activation in Parkinson’s disease (PD)
as shown by in vivo PET ligand such as 11C-PK11195. In addition, diffusion
tensor imaging (DTI) imaging reveals widespread changes in PD, especially
when the associated dementia develops. In the present case series, we studied
five subjects with Parkinson’s disease dementia (PDD). Our findings suggest
that while DTI metrics mirror cognitive severity, higher 11C-PK11195 binding
seems to be associated with a relative preservation of both white matter tracts
and cognition. Longitudinal studies are warranted to tackle the complex rela-
tionship between microglial activation and structural abnormalities in neurode-
generative conditions.
Introduction
Neuroinflammation is increasingly recognized as a key con-
tributor to neurodegeneration in Parkinson’s disease (PD)
and dementia.1 PET probes have been developed to assess
in vivo brain inflammation, for example, by targeting
translocator protein (TSPO).2 Among those, 11C-PK11195
is one of the most widely used ligands to estimate micro-
glial activation.3 Recent studies in Alzheimer’s disease (AD)
and dementia with Lewy bodies (DLB) have shown that
microglial activation, as measured with 11C-PK11195 PET,
is more prominent in patients at an earlier disease stage.4,5
Diffusion tensor imaging (DTI), on the other hand, is an
application of diffusion-weighted magnetic resonance
imaging designed to assess microstructural integrity based
on motion of water molecules. Impaired white matter
integrity in people with PD has been consistently observed
in corpus callosum, in relation to cognitive impairment
and development of dementia.6,7 In the present case series,
we studied 11C-PK11195 binding as an index of neuroin-
flammation, and its association with DTI, motor, and cog-
nitive features of Parkinson’s disease dementia (PDD).
Subjects and Methods
We studied five PDD subjects who were recruited within
the Neuroimaging of Inflammation in Memory and other
Disorders (NIMROD) study protocol.8 Demographics are
available in Table 1. Each subject underwent structural
MRI, 3T DTI, and 11C-PK11195 PET imaging, as well as
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in-depth neuropsychological and motor assessment,
including Addenbrooke’s Cognitive Evaluation Revised
(ACER) and Movement Disorders Society (MDS) Unified
Parkinson’s Disease Rating Scale (UPDRS) part III motor
assessment.
Mean cortical thickness was obtained with Freesurfer 6.0
using the standard processing pipeline described in.9 DTI
imaging was processed with FSL 6.0.10 Briefly, this included
registration of all diffusion-weighted images to the b = 0
(i.e., no diffusion) volume using the FMRIB Software
Library (FSL) Diffusion Toolbox, followed by brain masks
creation with Brain Extraction Tool, head movement, and
eddy currents correction. We then used DTIfit to indepen-
dently fit the diffusion tensor for each voxel, resulting in
the derivation of fractional anisotropy (FA), mean and
radial diffusivity (MD and RD, respectively).
Details about 11C-PK11195 PET processing are avail-
able in4. In brief, binding in each region of interest was
quantified using non-displaceable binding potential
(BPND) determined with a simplified reference tissue
model incorporating vascular binding correction and ref-
erence region time-activity curve estimation from super-
vised cluster analysis using four kinetic classes. Regional
BPND was corrected for CSF contamination through divi-
sion of the region of interest time-activity curve with the
mean region of interest fraction of grey and white matter.
Regional BPND binding was obtained for each subject
with the Hammers atlas.4,11
Subsequently, regional 11C-PK11195 binding Z-scores
were computed by comparing each PDD subject’s values
to 16 similarly aged control subjects (mean  SD age
69.7  6.6 years, 50% female participants, ACER score
92.5  5.6) scanned with the same imaging protocol,2
with Z-scores higher/lower than 2.0 considered as signifi-
cant. Spearman correlations and regression analyses were
performed in the PDD group between composite lobar
Table 1. Demographics, clinical, and imaging features of included PDD subjects.
Subject
Age (years),
Gender
MDS-UPDRS III,
ON-state ACER
DTI global radial
diffusivity
Significant 11C-PK11195 BPND changes
compared to Controls
PDD 1 78, M 36 86 5.11 9 104 Putamen (↑), substantia nigra (↓)
PDD 2 70, M 40 80 5.36 9 104 Parahippocampal gyrus (↓)
PDD 3 70, M 48 76 6.19 9 104 Substantia nigra (↓)
PDD 4 81, M 36 69 6.09 9 104 Midbrain (↓), medulla (↓)
PDD 5 68, M 34 85 4.83 9 104 Mesial anterior temporal lobe (↓),
fusiform gyrus (↓), superior parietal gyrus (↓),
lateral orbital gyrus (↓), amygdala (↓),
nucleus accumbens (↓), substantia nigra (↓), pons (↓)
Mean  SD 73.4  5.7 38.8  5.6 79.2  7.0 5.52 9 104
Figure 1. Axial 11C-PK11195 BPND images and T1-weighted structural MRI of the five PDD included in the study and one representative control
subject (65-year-old female participant, ACER 96/100). PDD patients have similar 11C-PK11195 binding than the control participants, except PDD
5 who has lower binding values in several regions (cf. Table 1).
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(frontal, temporal, parietal, occipital) and whole-cortex
11C-PK11195 BPND, DTI metrics, and clinical data. Given
the exploratory design of the study, results were not cor-
rected for multiple comparisons.
Results
Demographics and main findings are available in Table 1.
The analyses revealed that PDD subjects had comparable
or lower levels of whole-cortex as well as regional 11C-
PK11195 binding relative to controls (Fig. 1). In addition,
lobar occipital 11C-PK11195 binding was inversely corre-
lated with MD and RD after adjusting for mean cortical
thickness (linear regression, for MD: B = 415.6,
P = 0.035, adjusted R2 = 0.89; for RD: B coeffi-
cient = 348.6, P = 0.032, adjusted R2 = 0.90), that is,
higher 11C-PK11195 was associated with a relative preser-
vation of white matter integrity. The directionality of
these PET-MRI correlations was congruent with those
from neuropsychological data. In fact, ACER score posi-
tively correlated with frontal 11C-PK11195 binding when
adjusting for mean cortical thickness (linear regression,
B = 641.2, P = 0.014, adjusted R2 = 0.95). In addition,
there was a trend for higher ACER scores being related to
preserved DTI metrics (lower MD/RD and higher FA,
Spearman P = 0.10, rho = 0.80 for MD/RD and 0.80
for FA). There was no significant association between
MDS-UPDRS part III score and 11C-PK11195 binding or
DTI metrics.
Discussion
Our study suggests that higher 11C-PK11195 binding is
associated with a relative preservation of both white
matter tracts and cognition. Specifically, we found that
DTI metrics mirror disease severity, and that PDD
subjects had similar or reduced 11C-PK11195 binding
compared to controls.6,12 While these findings require
confirmation with larger samples, longitudinal data,
and finer imaging proxies (e.g., voxel-wise DTI associ-
ation with 11C-PK11195 binding), this case series
brings novel evidence for an early role of neuroinflam-
mation in the pathophysiology of PDD and confers
additional support for the hypothesis that central
inflammation represents a potential therapeutic target
in dementia.
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